Iyas S. Daghlas

Neurology

505 Parnassus Ave Box
Suite 0114
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 67 publications

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: JAMA neurology

Published: August 17, 2026

Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.

Direct Oral Anticoagulant Protein Targets and Risk of Cerebral Venous Thrombosis: A Mendelian Randomization Study.

Journal: Neurology

Published: March 05, 2026

Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial.

Observed Versus Predicted Stroke Risk After Transient Ischemic Attack: A Post Hoc Analysis of a Randomized Clinical Trial.

Journal: Journal of the American Heart Association

Published: February 20, 2026

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Anti-CD320 Autoantibodies and Central Nervous System Vitamin B12 Deficiency in Idiopathic Myelopathy.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease.

Genetically Predicted Levels of Lipoprotein(a) and Risk of Cerebrovascular Disease.

Journal: Journal of the American Heart Association

Published: January 29, 2026

Mendelian randomization applied to migraine research: Opportunities and challenges.

Mendelian randomization applied to migraine research: Opportunities and challenges.

Journal: Cephalalgia : an international journal of headache

Published: January 27, 2026

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.

Genetically proxied IL-6 signaling inhibition, lipoprotein(a) levels, and atherosclerotic disease risk.

Journal: Atherosclerosis

Published: January 21, 2026

Genetic Downregulation of Interleukin-6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease.

Genetic Downregulation of Interleukin-6 Signaling, Coagulation Function, and Risk of Thromboembolic Disease.

Journal: Journal of the American Heart Association

Published: December 11, 2025

Early onset rapidly progressive frontotemporal dementia due to a novel MAPT P301A variant with functional validation of pathogenicity.

Early onset rapidly progressive frontotemporal dementia due to a novel MAPT P301A variant with functional validation of pathogenicity.

Journal: NPJ dementia

Published: October 18, 2025

Clarification on MTHFR Variants and Ischemic Stroke Risk.

Clarification on MTHFR Variants and Ischemic Stroke Risk.

Journal: The Neurohospitalist

Published: October 15, 2025

Limitations to causal inference in observational studies of PFO closure.

Limitations to causal inference in observational studies of PFO closure.

Journal: European stroke journal

Published: August 25, 2025

Genetically reduced MTHFR activity confers protection against multiple sclerosis.

Genetically reduced MTHFR activity confers protection against multiple sclerosis.

Journal: Journal of neuroimmunology

Published: August 14, 2025

Showing 1-12 of 67

Last Updated: 09/26/2026